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Mutations in the human SLC26A4/Pendrin polypeptide (hPDS) cause Pendred Syndrome /DFNB4, syn-
dromic deafness with enlargement of the vestibular aqueduct and low-penetrance goiter. Here we
present data on cloning, protein overexpression and puriﬁcation, refolding, and biophysical character-
ization of the recombinant hPDS STAS domain lacking its intrinsic variable sequence (STAS-ΔIVS). We
report a reproducible protein refolding protocol enabling milligram scale expression and puriﬁcation of
uniformly 15N- and 13C/15N-enriched hPDS STAS-ΔIVS domain suitable for structural characterization by
solution NMR. Circular dichroism, one-dimensional 1H, two-dimensional 1H–15N HSQC, and 1H–13C HSQC
NMR spectra conﬁrmed the well-folded state of puriﬁed hPDS STAS-ΔIVS in solution. Heteronuclear
NMR chemical shift perturbation of select STAS-ΔIVS residues by GDP was observed at fast-to-inter-
mediate NMR time scales. Intrinsic tryptophan ﬂuorescence quench experiments demonstrated GDP
binding to hPDS STAS-ΔIVS with Kd of 178 μM. These results are useful for structure/function char-
acterization of hPDS STAS, the cytoplasmic subdomain of the congenital deafness protein, pendrin, as
well as for studies of other mammalian STAS domains.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
SLC26 family anion transport proteins are conserved throughout
phylogeny from bacteria to humans [1,2]. In prokaryotes and plants
this family of proteins is known as SulP (Sulfate Permease). SLC26
and SulP proteins consist of a short cytoplasmic N-terminus, a
complex polytopic transmembrane domain of 14 trans-bilayer
spans, and a cytoplasmic C-terminal region of 125–250 aa largely
comprizing a Sulfate Transporter and anti-Sigma factor antagonist
(STAS) domain [3]. The 10 known protein-coding human SLC26
genes encode anion transporters, exchangers and channels ex-
pressed in epithelial cells and other cell types throughout the body.
Mutations in at least four human SLC26 genes cause early-onset
Mendelian diseases, including chondrodysplasia (SLC26A2/DTD),
chloride-losing diarrhea (SLC26A3/DRA), deafness with enlargementB.V. This is an open access article u
ide; IVS, Intrinsic variable
lation spectroscopy; CD,
A.K. Sharma),of the vestibular aqueduct and low-penetrance goiter (SLC26A4/
pendrin), and a rare form of impaired male fertility (SLC26A8). Many
of these mutations involve the respective STAS domains. The human
disease phenotypes are modeled in knockout mice with varying
degrees of clinical ﬁdelity, and genetic inactivation in mice of other
Slc26 genes unassociated as yet with human disease also causes
pathogenic murine phenotypes. In addition, human SLC26A9 var-
iants have been identiﬁed as strong risk modiﬁers of cystic ﬁbrosis
lung disease, whereas human pendrin (hPDS/SLC26A4) has been
investigated as a risk modiﬁer of systemic ﬂuid balance, blood
pressure, and asthma [2].
The STAS domains of SLC26/SulP transporters are homologous
to bacterial anti-sigma factor antagonists such as SpoIIAA of B.
subtilis [4,5]. Anti-sigma factor antagonists counter the activity of
repressors (anti-sigma factors) of sigma (transcription) factors in
the bacterial sporulation stress response pathway [6]. STAS do-
mains are essential for plasmalemmal targeting, contribute to
anion transport function and, like bacterial anti-sigma factors,
serve as protein-protein interaction modules. Mutations in STAS
domains of mammalian SLC26 transporters and bacterial SulP
transporters impair function and/or surface expression of these
transporters [3,7,8–10].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lography include those from dicarboxylate and bicarbonate
transporter [11,12], DauA(YchM) of E. coli [13] and from di-
carboxylate transporter SLC26Dg [3], as well as a STAS-ΔIVS
structure from the cochlear outer hair cell Cl-dependent ampliﬁer
SLC26A5/prestin of rat [14]. NMR solution structures have been
solved for rat prestin STAS-ΔIVS [14] and for the intact putative
sulfate transporter Rv1739c of M. tuberculosis [15]. The presence of
the unstructured "intervening sequence" (IVS) located between
STAS helices α1 and β3 (nomenclature from [14]) distinguishes
mammalian and metazoan STAS domains from those of bacterial
anti-sigma factor antagonists and SulP transporters. No function
has yet been reported for the IVS, and its deletion was required for
protein overexpression and production of the ﬁrst STAS domain
crystals diffracting to high resolution [14]. All mammalian STAS
domains reported subsequently have lacked the IVS, and along
with bacterial STAS domains have yielded monomeric solution
structures. Two-dimensional 1H–15N HSQC spectra of wildtype and
mutant STAS from human SLC26A3/DRA have been presented
without NMR assignment [8].
In addition to their enabling contributions to SLC26-mediated
anion transport, SulP STAS domains are also nucleotide binding
proteins [12,15], as previously demonstrated for SpoIIAA and ASAs
[4,5]. Mammalian STAS domains have been shown to interact with
multiple proteins in pulldown assays, including CFTR [8], OASTL
(for A. thaliana Sultr1) [16] and IQGAP-1 [11]. Towards an under-
standing of the structural basis and functional utility of STAS do-
main nucleotide binding, we have initiated a structural char-
acterization of the hPDS/SLC26A4 STAS domain by heteronuclear
solution NMR, both in the absence and presence of the IVS. Here
we present data on the molecular cloning, puriﬁcation, and pre-
liminary structural characterization of recombinant hPDS STAS
domain lacking the IVS region (STAS-ΔIVS). The reported pur-
iﬁcation strategy yields well-folded hPDS STAS-ΔIVS in quantities
and of stability sufﬁcient for structural characterization by solution
NMR. We also report biophysical experiments that demonstrate
nucleotide binding by hPDS STAS-ΔIVS.2. Materials and methods
2.1. Molecular cloning of recombinant hPDS STAS domain (ΔIVS)
To delimit operational boundaries of the STAS domain of
SLC26A4/hPDS (Uniprot # O43511), the aa sequence of hPDS STAS
was aligned with STAS domains of other human SLC26 polypep-
tides and with other structurally characterized STAS domains
[5,17]. The secondary structure of hPDS STAS was predicted using
Psipred (http://bioinf.cs.ucl.ac.uk/psipred/). These analyses sug-
gested a STAS domain encompassing aa residues 517–734, with aa
575–652 as the IVS region. Initial hPDS STAS-ΔIVS constructs en-
compassing aa 512–780 (hPDSL STAS-ΔIVS) and aa 512–743 (hPDSS
STAS-ΔIVS) were cloned in-frame into pET52b(þ) (EMD Chemi-
cals) with a C-terminal His10-tag. A third STAS-ΔIVS construct
encompassing aa 517–738 (hPDSST STAS-ΔIVS) was cloned into
pET28-a(þ) in-frame with an N-terminal His6-tag. Digested liga-
tion products were transformed into E. coli BL21(DE3) cells (EMD
chemicals). Plasmid sequence integrity was validated by DNA se-
quencing. Recombinant DNA was quantitated by Nanodrop spec-
trophotometer (Thermo Scientiﬁc, Waltham, MA), and DNA size
and purity analyzed by 2% agarose gel.
2.2. Expression and isolation of puriﬁed hPDS STAS
E.coli BL21(DE3) cells harboring STAS-ΔIVS plasmids in pET52-
b(þ) and pET28-a(þ) were grown overnight in LB mediumcontaining kanamycin (30 μg/L). A 20 mL overnight inoculum was
added to 2 L LB medium. Cultures were maintained at 37 °C until
reaching OD 0.6–0.8. Protein expression was then induced by IPTG
(empirically optimized at 750 μM) for 16 h at 13 °C. Induced cells
were harvested by centrifugation (GSA rotor, Sorvall RC5B) at
6000 rpm for 15 min at 4 °C, and stored at 80 °C until further
use. Harvested cells were freeze–thawed and suspended in buffer
A (25 mM Tris-HCl, pH 8.5, 150 mM NaCl, 10 mM imidazole) sup-
plemented with complete protease inhibitor cocktail tablet
(Roche), 0.01% PMSF, and lysonase (Novagen) (10 μl/l cell culture),
then agitated 30 min at 4 °C, and sonicated (Branson digital soni-
ﬁer, S-450D) at 4 °C, 77 s cycles at 35% amplitude with 1 min on
ice between cycles.
2.3. Puriﬁcation of insoluble STAS-ΔIVS polypeptide
Lysate was centrifuged 30 min at 17,000 rpm at 4 °C to separate
soluble and insoluble (inclusion body-containing) fractions. SDS-
PAGE of preparations from all three STAS-ΔIVS constructs revealed
that each accumulated predominantly in inclusion bodies which
were washed 3x in buffer A and solubilized in buffer A containing
6 M Guanidine HCl. The cleared, denatured lysate was loaded onto
pre-equilibrated Ni-NTA columns (Qiagen). STAS-ΔIVS protein was
puriﬁed as previously described for Rv1739c STAS [18], except for
inclusion of 2 M urea in wash and elution buffers, and additional
modiﬁcations described in Supplementary Information. Eluate
fractions were evaluated by SDS-PAGE. STAS-ΔIVS-containing
fractions were pooled and dialyzed in refolding buffer B (25 mM
Tris-HCl, 50 mM NaCl, pH 7.9) at 4 °C with three buffer replace-
ments at 12 h intervals. The dialyzed STAS-ΔIVS protein was
subsequently puriﬁed by anion-exchange chromatography (Q-se-
pharose fast ﬂow matrix, GE Healthcare, Marlborough, MA). Pur-
iﬁed protein was eluted in buffer B with a salt gradient increasing
to 1 M NaCl. Q-sepharose eluates were dialyzed in buffer C (25 mM
Tris-HCl, 150 mM NaCl, pH 7.9).
Immunoblot analysis was performed with mouse monoclonal
anti-(His)6 antibody (Sigma-Aldrich, EMDMillipore, Billerica, MA)
diluted 1:3000. HRP-conjugated secondary antibodies (Sigma-Al-
drich) were diluted 1:1000. Proteins were separated on 16% SDS-
PAGE. ECL signal was detected with reagents from Amersham
Biosciences by Kodak X-omat 2000 A.
Protein puriﬁcation was assessed by size exclusion chromato-
graphy using a Biologic Duo ﬂow FPLC system (Bio-Rad) at 4 °C on
a Superdex 75 column (Amersham Biosciences) of 125 mL bed
volume at 1 mL/min ﬂow-rate, pre-calibrated with molecular
weight standards (Bio-Rad) and pre-equilibrated in buffer C.
For expression of 15N-enriched protein constructs, E.coli BL21
(DE3) cells harboring hPDSST STAS-ΔIVS plasmid in PET28-a(þ)
were grown in M9 minimal media containing 15NH4Cl (1 g/l),
12C-glucose (2 g/l) (Cambridge Isotope Laboratories; CIL) supple-
mented with 10 mL/L Bioexpress cell growth media (U-15N, 98%;
10x concentrate, CIL) as sole carbon and nitrogen sources. 13C/15N-
enriched STAS-ΔIVS proteins were produced using 15NH4Cl (1 g/l),
13C-glucose (2 g/l), and U-15N, 13C (98%, 10x concentrate. CIL).
Puriﬁcation of 15N or 13C/15N-enriched hPDSST STAS-ΔIVS was
conducted by methods identical to those used for unlabeled pro-
tein. The His6-tag was removed by thrombin cleavage (GE
Healthcare; 2U/mg, 16 h at 4 °C), then quenched by 1 mM PMSF.
Tag-free hPDSST STAS-ΔIVS protein was recovered from repassing
the cleaved reaction mixture through freshly prepared, buffer
B-equilibrated Ni-NTA beads. For solution NMR experiments,
samples additionally puriﬁed by anion exchange chromatography
were dialyzed in Buffer D (40 mM potassium phosphate, 150 mM
NaCl, pH 6.25). Puriﬁed hPDSST STAS-ΔIVS samples were stable at
pH 6.2, allowing collection of high quality heteronuclear NMR data
of good signal-to-noise ratio. Puriﬁed STAS-ΔIVS protein was
Table 1
Primer sequences used in PCR ampliﬁcations of IVS excluded regions of hPDS STAS.
Mutagenesis primers #1–5 were to amplify STAS-ΔIVS sequences for cloning
hPDSL and hPDSS constructs into pET52b. Primers #6 and 7 were used to shuttle
hPDSST STAS sequence (excluding disordered IVS region) from pET52b(þ) into pET-
28a(þ) for structural studies.
SLC26A4
STAS
Primer sequence
1. mut_For 5′-GACTGTGACCTTGCCATGGCGAGAGTTCAGTTTCCTTCTTGG-3′
2. mut_Rev 5′-GCGTGGCACCAGAGCGAGCTCGGATGCAAGTGTACGCATAGC-3′
3. mu-
t_Rev-
short
5′-GCGTGGCACCAGAGCGAGCTCTAAAATGGAACCTTGACCCTC-3′
4. mut-
fuse_Rev
5′-GCACAAGGCTATGGATTGGCACGGCATCAAATCCAACTGTGGAC-3′
5. mut-
fuse_For
5′-GTCCACAGTTGGATTTGATGCCGTGCCAATCCATAGCCTTGTGC-3′
6. 28a_For 5′-TCACATATGGCTAGCTCTTGGAATGGCCTTGGAAGC-3′
7. 28a_Rev 5′-CAGGAGCTCGAATTCCTAACCCTCTTGAGATTTCACTTG-3′
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con 10 kDa NMWL membrane centrifugal devices (Millipore), then
quantitated by Bradford assay [19].
2.4. MALDI-TOF MS
hPDSST STAS-ΔIVS protein identity and homogeneity were
tested by MALDI-TOF MS by determination of the m/z ratio on an
AB/MDS Sciex 4800 Plus MALDI TOF/TOF Analyzer (Applied Bio-
systems, Carlsbad, CA). His6-tagged protein was diluted 1:20 into a
solution of standard MALDI matrix sinapinic acid (prepared from
5.0 mg/mL stock), spotted onto the 4800 OptiTOF metal target
plate and dried. Data were collected as total ion current (TIC) from
500 laser shots.
2.5. CD spectroscopy
Protein folding and intrinsic secondary structural character-
istics of recombinant hPDSST STAS-ΔIVS domain were assessed by
Far-UV (260–190 nm) CD measurements at 25 °C on a Jasco-810
spectropolarimeter (Tufts University School of Medicine, Boston,
MA). Anion exchange chromatography-puriﬁed and Buffer C-dia-
lyzed sample was used for CD analysis. Prior to data collection,
protein samples were clariﬁed by centrifugation at 13,000 rpm,
1 min, 4 °C (Eppendorf 5424 R). Data were collected using a 1 mm
path length quartz cuvette (Starna Cells, Atascadero, CA) with
1 nm bandwidth, 2 s response time, 20 nm/min scan speed, and
4 scans in continuous mode. Buffer-corrected spectra were re-
corded for 23 μM STAS-ΔIVS. Data were converted into Molar
Residue Ellipticity (MRE) in units of θ (deg cm2 dmol1) and
analyzed using the program K2D2 [20]. Data were collected in
triplicate and averaged for analysis.
2.6. Solution NMR spectroscopy
One-dimensional 1H, 2D 1H–15N HSQC [21] and 1H–13C HSQC
(constant time t1 evolution) [22] NMR experiments were per-
formed at 27 °C on a Bruker Avance spectrometer operating at 1H
frequency 600.133 MHz equipped with a 5 mm triple resonance
(z-axis) pulsed-ﬁeld gradient probe. NMR samples of 15N or
13C/15N-enriched STAS domains (0.25 mM) contained 10% (v/v)
D2O, 1 mM DTT-d10, 0.25 mM DSS as internal standard, 0.05% (w/
v) NaN3, and 1X protease inhibitor. One dimensional 1H NMR
spectrum was acquired using a zgcppr pulse sequence with a
presaturation scheme for water suppression employing a compo-
site pulse. 512 scans were collected for 1D 1H NMR data inter-
pretation. 2D 1H–15N HSQC spectra were acquired using a relaxa-
tion delay of 1.00 s, with 8 scans (39 min acquizition time), 32
scans (2 h 45 min acquizition time) or 128 scans (10.3 h acquizi-
tion time). The 2D 1H–13C HSQC spectrum was acquired using the
Echo-AntiEcho mode of quadrature detection (13C dimension),
with respective spectral widths of 13 ppm and 80 ppm in 1H and
13C dimensions. Data were processed on an Intel PC workstation
running OpenSuse11.1 using NMRPipe/NMRDraw processing soft-
ware [23]. A Gaussian ﬁlter with a line-broadening parameter of
12 Hz was applied in direct and indirect acquired dimensions. All
data sets were zero-ﬁlled once in each dimension to yield a ﬁnal
matrix of 2048*256 real data points. All 1H chemical shift values
were referenced with respect to internal standard DSS [24]. NMR
data were analyzed with NMRDraw [23] and CCPNMR [25]. The
hPDSST STAS-ΔIVS interaction with GDP nucleotide was measured
by collecting a series of 2D 1H–15N HSQC experiments of 32 scans.
hPDSST STAS-ΔIVS (0.25 mM) was titrated with nucleotide to a
saturating concentration of 20 mM.2.7. Fluorescence spectroscopy
One native Trp and six native Tyr residues of hPDSST STAS-ΔIVS
served as intrinsic ﬂuorescence intensity probes. STAS protein pur-
iﬁed by Ni-afﬁnity- and anion exchange chromatography was used in
Buffer C for ﬂuorescence experiments. Samples were centrifuged
before use. GDP free acid (Sigma) of highest available purity was
prepared as stock solutions in buffer A. hPDSST STAS-ΔIVS (20–
23 μM; initial volume 200 mL) was preincubated in 48-well plates at
24 °C with nucleotide. Steady-state intrinsic ﬂuorescence intensity of
hPDSST STAS-ΔIVS was then recorded at λem 290–400 nm at 2-nm
intervals with ﬁxed λex 280 nm (SpectraMax M5, Molecular Devices,
Sunnyvale, CA) in the presence of sequentially increasing nucleotide
concentration, or titrated with buffer C alone. Protein and ligand were
mixed and agitated 15 min prior to data collection. hPDSST STAS-ΔIVS
ﬂuorescence at each nucleotide concentration was corrected for di-
lution and for inner ﬁlter effect (IFE) contributions of added nucleo-
tide, on the intrinsic ﬂuorescence of a mixture of a free tryptophan
plus 6 M eq of free tyrosine (the 1:6 Trp: Tyr molar ratio reﬂected in
the native hPDSST STAS-ΔIVS aa sequence), with identical data ac-
quizition parameters and instrument settings, as described [26]. IFE
corrected and normalized ﬂuorescence intensities were plotted as a
function of nucleotide concentration and ﬁt (SigmaPlot, Systat) to a
single site ligand-binding model to determine dissociation constant
(Kd) as described for nucleotide binding by Rv1739c STAS [15].3. Results and discussion
3.1. Molecular cloning of hPDS STAS domain
All the primers used in this study are shown in Table 1. We
initially planned NMR structural characterization of hPDS STAS-
ΔIVS using two STAS constructs hPDSS (aa 512–743) and hPDSL (aa
512–780) as shown in Fig. 1. Empirical testing of these STAS-ΔIVS
constructs revealed low protein yields with high tendency to
precipitate during dialysis for imidazole removal (see below). In
view of the potentially destabilizing role of N-terminal Arg 512 of
the above STAS constructs, we generated hPDSST STAS-ΔIVS con-
structs in pET-52b(þ) and in pET28a(þ) (Supplementary Fig. S1)
that preserved the predicted secondary structure of the longer
constructs (see Supplementary Fig. S2).
3.2. Expression and isolation of hPDS STAS domain
Growth and induction of E. coli expressing STAS-ΔIVS poly-
peptides hPDSL, hPDSS, and hPDSST respectively yielded 3.6, 3.3,
A.K. Sharma et al. / Biochemistry and Biophysics Reports 8 (2016) 184–191 187and 3.3 g wet cell paste per liter culture. SDS-PAGE revealed bands
of expected size (in kDa) for hPDSL (24.3), hPDSS (20.1) (data not
shown), and for hPDSST (18.8; Fig. 2A). Protein induction was more
efﬁcient at 13 °C than at 25 °C or 37 °C. Polypeptide products of
each construct partitioned 95% into the insoluble fraction.
Inclusion body lysates were bound to Ni-NTA beads, and eluted
with imidazole step gradients. Yields of eluted of STAS-ΔIVS
polypeptide were 28% for hPDSL, 21% for hPDSS, and 53% hPDSST.
The larger imidazole-resistant retained fractions of STAS-ΔIVSFig. 1. Amino acid (aa) sequence encoded by SLC26A4/hPDS STAS domain cDNA used fo
associated missense mutations. Underlined aa sequence corresponds to the structurally
Fig. 2. Protein expression and puriﬁcation, mass and CD spectra of hPDSST STAS-ΔIVS. Co
w/v) in the presence of 50 mM DTT; Lane M, protein standards; lane L, Lysate post-IPTG
4 °C, 1hr; lane P, insoluble (pellet) fraction after centrifugation; lane W, wash fraction fr
Imidazole in 500 mM NaCl). (B) Immunoblot showing protein monomer (p), dimer (2p
fractions in the absence of reducing agent (lanes 2 and 3) show a similar pattern (band
fractionated by anion exchange chromatography and separated in the presence of 50 m
standards; Lanes E1&E2, eluate fractions. (D) Mass spectroscopic chromatogram show
Kþ-adducts. A doubly charged species near 9.5 kDa is also seen. Additional peaks of hig
at 25 °C.constructs hPDSL and hPDSS were not released even upon addition
of 0.1% (w/v) octyl glucoside (OG) or dodecyl maltoside (DM).
Moreover, as much as 88% of initially soluble Ni-NTA-puriﬁed
STAS-ΔIVS constructs hPDSL and hPDSS precipitated during dia-
lysis. The remaining soluble protein was too unstable to allow
completion of CD experiments. Puriﬁcation in buffers containing
OG or DM marginally improved protein yield, but CD spectra of
these preparations revealed absence of well-folded protein (not
shown). We therefore focused subsequent efforts on puriﬁcationr molecular cloning and protein expression. Highlighted in red are sites of disease-
uncharacterized IVS region (aa 575–652), believed to be disordered.
nstruct includes N-terminal (His)6-tag. (A) Coomassie blue-stained SDS–PAGE (12%
induction at 13 °C; lane S, supernatant fraction after centrifugation at 17,000 rpm,
om STAS-bound Ni-NTA beads; lane E, STAS-ΔIVS eluted from Ni-NTA by 500 mM
), and higher order oligomer bands (h) in lane 1. Size exclusion chromatography
labeling similar to lane 1 on 16% w/v SDS-PAGE). (C) hPDSST STAS-ΔIVS in 1 M NaCl
M DTT on SDS–PAGE (4–20% w/v), then Coomassie blue-stained. Lane M, protein
s 19.1 kDa monomer peak of His6-hPDSST STAS-ΔIVS and 38.2 kDa dimer peak as
her mass may represent aggregates. (E) Far-UV CD spectrum of hPDSST STAS-ΔIVS
Fig. 3. (A) One-dimensional NMR spectrum of a uniformly 15N-enriched sample of
hPDSST STAS-ΔIVS. The proton signals above 9.0 ppm and below 0.5 ppm indicate
protein in a compact folded state. Methyl proton signals below 0.0 ppm likely re-
ﬂect ring current effect (arising from interaction with aromatic ring protons), fur-
ther supporting the folded state in these solution conditions. Inset shows magniﬁed
region of methyl peaks below 0.0 ppm. (B) Heteronuclear two-dimensional 1H–15N
HSQC spectrum of hPDSST STAS-ΔIVS. The 5 additional crosspeaks seen at higher
contour level are highlighted as circled X's. Horizontal lines connect side chain
1H–15N correlation crosspeaks arising from Asn and Gln residues.
A.K. Sharma et al. / Biochemistry and Biophysics Reports 8 (2016) 184–191188and characterization of hPDSST STAS-ΔIVS (see Supplementary
Table. S1). All the data presented below are from this construct.
Immunoblot of samples in near physiologic salt concentration
demonstrated both monomeric and dimeric forms of hPDSST STAS-
ΔIVS (Fig. 2B), with some higher order oligomers. hPDSST STAS-ΔIVS
exhibited less precipitation during dialysis (o23%) than did larger
STAS-ΔIVS polypeptides. Size exclusion chromatography revealed
oligomeric forms of protein in solution, corroborating the im-
munoblot data.
Protein fractionated by size exclusion chromatography was sub-
jected to dialysis for subsequent anion exchange chromatographic
puriﬁcation, with o7% precipitation during dialysis. Reducing SDS-
PAGE of 1 M NaCl eluates from anion exchange chromatography
revealed only monomers, suggesting that high salt can shift the
conformational equilibrium towards the monomeric state (Fig. 2C).
Reducing [NaCl] to r150mM restored oligomeric heterogeneity.
Maintaining [NaCl]Z500 mM reliably reduced oligomerization of
hPDSST STAS-ΔIVS.
3.3. Yields of His6-tag-free STAS hPDSST polypeptide
His6 tag removal from the STAS-ΔIVS polypeptides led to major
protein loss (o25% recovery). Tag-free samples exhibited moder-
ate precipitation at later stages of puriﬁcation, and resulting
sample quantities were insufﬁcient for 1D 1H NMR studies.
Therefore, further attempts to optimize puriﬁcation of His-tag-free
STAS-ΔIVS polypeptides were discontinued.
3.4. MALDI-TOF MS
Mass spectrometry of hPDSST STAS in buffers lacking reducing
agent was not successful. Data collected in sample buffers con-
taining Z 9 mM tris-carboxyethylphosphine resulted in mass
detection of potassiated monomeric and dimeric species of protein
(Fig. 2D), accompanied by 2 forms of uncertain oligomeric
stoichiometry.
3.5. CD spectroscopy
Fig. 2E shows the CD spectrum of hPDSST STAS-ΔIVS. The data
show secondary structural elements suggesting a folded con-
formation in solution. The characteristic double ellipticity minima
at 208 and 220 nm are diagnostic for helical structure. The spectral
lineshape pattern, including the noted ellipticity differences at the
two minima, shows the presence of β-strand structure. Spectral
deconvolution analysis predicts that secondary structural ele-
ments constitute 41% of the polypeptide. Correcting for the
His6-fusion tag at the N-terminus, the measured % secondary
structure is close to that predicted ( 46%) from the hPDSST STAS-
ΔIVS model built on the rat prestin STAS-ΔIVS template. These
results show that puriﬁed, recombinant hPDSST STAS-ΔIVS poly-
peptide refolded from inclusion body lysate adopts a well folded,
structured conformation in solution.
3.6. NMR spectroscopy of hPDSST STAS domain
The folded state of hPDS STAS was further examined by ap-
plying 1D 1H and 2D heteronuclear solution NMR methods (Fig. 3).
First we attempted 2D 1H–15N HSQC spectra on the hPDSST STAS-
ΔIVS sample in buffer C, pH 7.9 (as used for CD measurements).
Although the data showed good dispersion of 1H–15N correlation
crosspeaks of weak intensity on a directly detected dimension, the
observed number of 1H–15N backbone correlation crosspeaks in
the 2D 1H–15N HSQC spectrum was less than half the expected 140
non-proline residues (see Fig. S1 for aa sequence of STASST-ΔIVS),
likely due to amide proton exchange with solvent and/or to thepresence of higher order STAS-ΔIVS oligomers in solution. The
results nonetheless suggested a folded state for puriﬁed protein in
this condition. Empiric assessment of buffer pH-dependence of
STAS-ΔIVS stability in solution led to subsequent NMR data col-
lection at pH 6.2.
One-dimensional 1H NMR spectrum dispersion of 10.80–
6.50 ppm clearly demonstrates a folded conformation of hPDSST
STAS-ΔIVS in solution (Fig. 3A). The moderately sharper line-
widths of most peaks within the backbone amide region suggests
the likely predominance of monomeric protein. The few peaks at
4.5–6.0 ppm likely correspond to 1Hα resonances of residues con-
stituting β-strand structures in the protein structure fold, corro-
borating the CD data. Select 1H peaks below 0.0 ppm probably
represent methyl proton peaks of residues experiencing a ring
current shift due to interaction with aromatic residue ring protons
within the tertiary structural fold (region magniﬁed in Inset).
These parameters show that hPDSST STAS-ΔIVS is well-folded,
with regions of tertiary structure.
The 2D 1H–15N HSQC spectrum of STAS-ΔIVS (Fig. 3B) shows at
least one 1H–15N backbone correlation crosspeak for most of the
polypeptide's non-proline amino acid residues. The 1H–15N side-
chain correlations from Asn, Gln, and Trp residues are also evident
in the spectrum. The chemical shift dispersion of these correlation
crosspeaks for a well-folded STAS domain may exhibit a dispersed
1H ppm spectral window (Fig. 3B), which for an intrinsically dis-
ordered or unfolded/partially folded protein would shrink to a
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HSQC spectrum (10.3 h acquizition at pH 6.2) shown in Fig. 3B
exhibits 151 cross-peaks (excluding the side-chain correlations)
and excellent chemical shift dispersion of 10.83–6.57 1H ppm. Five
additional backbone 1HN correlations crosspeaks of higher contour
are also evident (circled X's in Fig. 3B). The 1H–15N HSQC spectra
recorded at shorter acquizition time (Supplementary Table S3)
shows complete crosspeak dispersion similar to that of the longer
acquizition time spectrum. Maintenance of spectral quality during
1 week of sample storage suggests stability of protein conforma-
tion at 0.25 mM during this time.
The expected number of 1H–15N backbone correlation crosspeaks
for this construct (Fig. S1) is 162, including 23 1H–15N correlation
crosspeaks predicted to arise from the N-terminal cleavable
(His)6-fusion tag. The 156 crosspeaks detected in the spectrum likely
include all or most core protein resonances. Two sets of crosspeaks
of different intensity distributions were present in the spectrum. The
predominant set of 130 crosspeaks shows moderately sharper
linewidths, whereas, the minority set of 26 crosspeaks has
broader linewidths of intensity at least 50% lower than the average
intensity of the majority set of crosspeaks. These differences in
linewidth might reﬂect different dynamic properties elicited by the
respective resonances. The weaker intensity crosspeaks could in-
clude some or all 1H–15N resonances from the (unstructured) (His)6
tag region, and/or could reﬂect solvent exchange effects for these 1HN
resonances. Although protein aggregation was operationally mini-
mized at pH 6.2, a degree of oligomerization producing slower ro-
tational correlation times of minority set of crosspeaks cannot be
ruled out. Future completion of NMR assignment will provide fur-
ther details.
Fig. 4 shows the well-dispersed 2D 1H–13C HSQC spectrum of
hPDSST STAS-ΔIVS. Downﬁeld-shifted 1H–13C correlation cross-
peaks within the 1Hα region likely indicate signals from residues
involved in β-strand formation. The extreme upﬁeld-shifted
crosspeaks (below 0.0 ppm) identify residues likely exhibiting a
ring current shift effect, corroborating the 1D 1H NMR data. These
data together suggest that hPDSST STAS-ΔIVS adopts a folded
conformation in solution.Fig. 4. Heteronuclear 2D 1H–13C HSQC spectrum of hPDSST STAS-ΔIVS. 1H–13C
correlation crosspeaks are well-dispersed. Downﬁeld shifted 1H–13C correlation
crosspeaks within 1Hα region likely indicate signals from residues involved in β-
strand formation. The extreme upﬁeld-shifted crosspeaks (below 0.0 ppm) likely
identify residues exhibiting ring current shift effect, and corroborate the 1D 1H
NMR data presented here.3.7. NMR detection of nucleotide binding by hPDSST STAS
The nucleotide-binding properties of anti-s factor antagonist
SpoIIAA [27], STAS domain of Rv1739c from M. tuberculosis [15],
and STAS domains from full-length YchM/DauA [12] prompted
evaluation of nucleotide binding by hPDSST STAS-ΔIVS.
We ﬁrst tested stability of NMR samples by collecting a series of
2D 1H–15N HSQCs (2 h 45 min each) at days 1, 3, 4, and 7 after
puriﬁcation, with storage at 4 °C. All 2D 1H–15N HSQC spectra re-
vealed similar degrees of dispersion, with minimal precipitation
over the 7 d period. These data warranted preparation of 13C/15N
doubly-enriched NMR sample for resonance assignment and
structural characterization.
In order to study hPDSST STAS-ΔIVS interaction with nucleotide
by NMR chemical shift perturbation (CSP), 2D 1H–15N HSQC
spectra of freshly prepared 15N-STAS-ΔIVS were collected in the
presence of sequentially increasing [GDP]. Data revealed GDP-in-
duced NMR chemical shift perturbation (CSP) for select protein
residues. NMR titration experiments identiﬁed 20 mM GDP as a
saturating concentration for hPDS STAS-ΔIVS, as higher con-
centrations did not signiﬁcantly increase CSP (not shown). Overlay
of 2D 1H–15N HSQC spectra of STAS-ΔIVS domain in the absence
and presence of increasing [GDP] is shown in Fig. 5A. Sections of
the spectrum with residues exhibiting the largest GDP-induced
CSPs are enlarged in Fig. 5B–D. GDP-induced conformational per-
turbations include resonances showing only weighted average
peak shifts, whereas other select resonances exhibit peak shifts
accompanied by decreased crosspeak intensity. GDP addition to
STAS-ΔIVS also elicited emergence of several novel resonances
(Fig. 5A and B) probably reﬂecting nucleotide-induced stabiliza-
tion of normally undetected, ﬂexible residues, and/or slow con-
formational exchange of select residues in their local environ-
ments. These analyses suggest that GDP binding induces CSP of
select protein residues, a process that occurs at faster-intermediate
NMR time scales. Taken together, these results strongly suggest
that hPDSST STAS-ΔIVS binds guanine nucleotide.
3.8. Nucleotide binding by hPDSST STAS-ΔIVS by intrinsic ﬂuores-
cence quench
The presence in hPDSST STAS-ΔIVS (Fig. 1) of a single Trp residue,
Trp518, and 6 Tyr residues (Tyr530, Tyr536, Tyr556, Tyr691, Tyr698,
and Tyr728) allowed assessment of nucleotide binding by intrinsic
ﬂuorescence quench. hPDSST subjected to 280 nm excitation ex-
hibited a ﬂuorescence emission λmax of 320 nm. Fig. 6A illustrates
the gradual quench of intrinsic STAS ﬂuorescence with progressively
increasing concentrations of GDP, with maximum observed quench
of 14.2%. The observed quench isotherm is compatible with a single
nucleotide binding site of K1⁄2¼178781 μM (Fig. 6B). The data
suggest a nucleotide interaction surface in STAS domain that directly
or indirectly perturbs Trp and/or Tyr residues through conforma-
tional effects on adjacent or interposed residues. These results are
consistent with the heteronuclear NMR data showing nucleotide
binding by hPDSST STAS-ΔIVS. Similar future experiments will ex-
amine nucleotide binding of full-length wild type and disease-as-
sociated mutants, and deﬁne the nucleotide binding surface of the
protein. Preliminary data (Sharma et al., unpublished) conﬁrm nu-
cleotide binding by the recombinant full-length STAS domain of A.
thaliana sulfate transporter SULTR1;2, further strengthening the
hypothesis that STAS domains are nucleotide binding proteins [4].
The tendency of hPDSST STAS-ΔIVS to aggregate was modulated
by salt concentration and pH. Buffer conditions of Z500 mM NaCl
and pH 6.2 each reduced protein aggregation. At 150 mM NaCl, the
protein exhibited a similar monomer-dimer equilibrium at both pH
6.2 and pH 7.9. SLC26A/SulP proteins in solution are known to ex-
hibit dimeric and higher order oligomeric structures [2,12,28]. Rat
Fig. 6. Intrinsic tryptophan/tyrosine ﬂuorescence quench (A) Intrinsic ﬂuorescence quench of hPDSST STAS-ΔIVS (20–23 μM) by indicated [GDP]. (B) GDP concentration
dependence for quench of hPDSST STAS peak intrinsic ﬂuorescence at 320 nm, with K1⁄2¼178781 μM. Values are mean7S.E. (n¼3).
Fig. 5. NMR detection of GDP interactions with hPDSST STAS-ΔIVS. (A) Superposition of 2D 1H–15N HSQC spectra of hPDS STAS in absence (black contours) and presence of
20 mM GDP (red contours). Chemically perturbed 1H–15N correlation resonances are indicated by circles, ellipses, and boxes. Arrows show emergent resonances in GDP-
saturated STAS spectra. Arrowed circles denote resonances showing CSP with decreased intensity. The guanine proton peak is at 8.09 ppm. (B and C) Magniﬁed regions of
boxed portions of 2D 1H–15N HSQC of STAS-ΔIVS in absence (black) and presence of (saturating) 20 mM GDP (red). (D) Tryptophan side-chain 1H–15N correlation crosspeaks
showing graded perturbation upon titration with increasing [GDP] (scale below panel).
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a tendency toward formation of higher molecular weight aggregates
[29]. Recombinant mouse Slc26a9 STAS also exhibited a monomer-
dimer equilibrium [30]. Protein aggregation was noted for E. coli
DauA STAS domain variants harboring mutations at the sites
homologous to the disease-associated mutations in SLC26 STAS
domains [31]. Future studies will test the role of the three Cys re-
sidues of hPDS STAS (aa 565, 662, and 706) in STAS oligomerization.
Rat prestin STAS template-based modeling of hPDS STAS-ΔIVS
suggests occupancy of ﬂexible loop positions by the three homo-
logous Cys residues (Cys706 is the ﬁrst residue in helix α3) with side
chain exposure to the solvent environment (Supplementary Fig. S4).
Thus, alterations in solvent pH, salt concentration, and redox en-
vironment may inﬂuence the native cysteine-cystine equilibrium,
including possible inter-monomer cystine linkage.
IVS deletion from the hPDS STAS domain has allowed a re-
producible puriﬁcation protocol, yielding well-folded protein inquantities suitable for NMR structural studies. Attempts are currently
underway to purify full-length hPDS STAS domain polypeptide from
soluble fractions in quantity sufﬁcient for solution NMR, using solu-
bility-enhancing fusion tags. However, the present study shows that
the IVS region is dispensable for nucleotide binding by hPDS STAS.4. Conclusions
The class of eukaryotic STAS domains from rodent and human
SLC26 transporters has proven difﬁcult to express in a well-folded
conformation at the high concentrations required for structural stu-
dies. With the exception of rat SLC26A5/prestin, only one 1H–15N 2D
HSQC spectrum has been reported from a mammalian STAS domain
(SLC26A3). However no structural information has been reported for
SLC26A3 STAS domain, perhaps reﬂecting low sample solubility [8],
or for STAS domain from any human member. Here we have
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and protein folding characterization of hPDSST STAS-ΔIVS as char-
acterized by CD and by 1D and 2D heteronuclear NMR. Our pur-
iﬁcation protocol has yielded well-folded U-13C/15N labeled re-
combinant STAS in the milligram quantities sufﬁcient for future un-
ambiguous NMR residue assignment and elucidation of three di-
mensional structure of this deafness gene product, SLC26A4/pendrin.
We found that hPDSST STAS-ΔIVS exists in solution in monomer and
dimer states, with propensity to higher-order oligomerization. We
showed by intrinsic ﬂuorescence quench and by CSP NMR methods
that hPDS STAS-ΔIVS can bind GDP. These results are of importance
not only for structure/function studies of hPDS STAS, but may in
addition be applicable to STAS domains of other human SLC26 anion
transporter polypeptides. This information will increase our under-
standing of a known therapeutic target for treatment of congenital
deafness. It will also increase understanding of an underappreciated
major pathway for distal nephron chloride reabsorption representing
an important target for diuretic development, with implications for
enhanced management of ﬂuid overload in settings of trauma and
intensive care, and in chronic cardiac, renal, and liver diseases.Funding sources
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